enGene Updates Corporate Presentation with New LEGEND Data, Reiterates Cash Runway
ENGN sits 30% above its 52-week low of $1.4.
Summary
enGene Therapeutics updated its corporate presentation with new interim Phase 2 LEGEND data showing a 54% complete response rate for detalimogene, a favorable safety profile, and progress on a surfactant-enhanced cohort. The company reiterated $285 million in cash, expected to fund operations through potential BLA filing and approval.
Key Events · Product Development and Regulatory · ENGN
-
New LEGEND Interim Data
Pivotal Cohort 1 showed a 54% complete response rate at any time—the primary endpoint—with 91% of CRs occurring at the first assessment and 96.8% of patients free from progression to ≥T2 disease. The safety profile was favorable, reflected in low treatment interruption (2.4%) and discontinuation (2.4%) rates.
-
Surfactant Cohort Progress
The first patients have been enrolled in a LEGEND cohort evaluating detalimogene combined with a polidocanol surfactant bladder rinse. Preclinical data suggest this approach could increase IL-12 expression more than tenfold, potentially improving both efficacy and durability.
-
Cash Runway Reiterated
Management highlighted $285 million in cash, cash equivalents, and marketable securities, which is expected to provide operating flexibility through a potential BLA filing and approval.
-
Near-Term Catalysts
A 12-month data update from the pivotal cohort and initiation of the BLA are expected in the second half of 2026, with potential approval and platform designation in 2027.
Analysis · ENGN · Life Sciences
enGene Therapeutics filed an updated corporate presentation that includes new interim Phase 2 LEGEND trial results for detalimogene in high-risk NMIBC. The data show a 54% complete response rate at any time, with a favorable safety profile and low progression to advanced disease. The presentation also highlights progress on a surfactant bladder rinse cohort designed to boost efficacy, and reiterates $285 million in cash expected to fund operations through a potential BLA filing and approval. This update comes just one month after a drastic 50% workforce reduction and executive departures, making the clinical progress and cash runway reassurance critical for investor confidence.
At the time of this filing, ENGN was trading at $1.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $121.9M. The 52-week trading range was $1.40 to $12.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.